Solid Tumor Targeting CAR-T Development Services: Target Immune Checkpoint

Online Inquiry

Background Service What We Can Offer Workflow Distinctive Services Highlights FAQs Contact

Creative Biolabs offers a comprehensive Solid Tumor Targeting CAR-T Development Service, designed to overcome immune checkpoint–mediated suppression within the tumor microenvironment. Our platform enables the generation of high-potency, exhaustion-resistant CAR-T cells through advanced genetic engineering strategies, including checkpoint knockout and autocrine secretion of inhibitory checkpoint fragments. By restoring sustained effector function and persistence in hostile TME conditions, this service supports the development of resilient CAR-T candidates with improved anti-tumor efficacy. We deliver end-to-end solutions spanning construct design, cell engineering, functional validation, and translational support to help unlock the full potential of adoptive cell therapy in solid tumors.

Introduction

The primary limitation of CAR-T therapy in solid tumors is the induction of T-cell exhaustion via the PD-1/PD-L1 axis. Research demonstrates that blocking these checkpoints, either through extrinsic antibodies or intrinsic genetic modulation, can significantly restore T-cell activation, proliferation, and tumor-killing capabilities. Creative Biolabs leverages this literature-backed strategy to enhance CAR-T persistence and complete response rates in challenging malignancies.

Combined immunotherapy enhances the killing of tumors. (OA Literature)
Fig.1 Combination immunotherapy potentiates tumor killing efficacy.¹

Service

Creative Biolabs' Solid Tumor Targeting CAR-T Development Services: Target Immune Checkpoint are designed to address the key biological barriers that limit CAR-T efficacy in solid tumors. Beyond conventional CAR engineering, we integrate immune checkpoint focused strategies to enhance T-cell persistence, functionality, and resistance to the immunosuppressive tumor microenvironment.

Our platform enables the development of armored CAR-T cells through multiple customizable approaches, including the disruption of PD-1 or CTLA-4 genes, the expression of dominant-negative receptors, checkpoint switch receptors, and the co-expression of immune-modulatory molecules. These strategies effectively prevent exhaustion and senescence, allowing CAR-T cells to maintain cytotoxic activity under chronic antigen stimulation. In parallel, we support the incorporation of cytokine support modules and optimized signaling domains to further improve proliferation and survival in solid tumor settings.

Creative Biolabs provides comprehensive support across the entire development pipeline, from target and construct design to in vitro functional validation and in vivo efficacy evaluation using relevant solid tumor models. Our services include immune checkpoint expression profiling, CAR-T phenotyping, exhaustion marker analysis, and tumor infiltration assessment.

Discover How We Can Help - Request a Consultation.

Technical Capabilities

Technical capabilities of Solid Tumor Targeting CAR-T Development Services. (Creative Biolabs Original)

Workflow

Required Starting Materials: Provide your Target Antigen sequence and preferred Checkpoints. For early‑stage projects, a description of the tumor type is acceptable.

Workflow of Solid Tumor Targeting CAR-T Development Services. (Creative Biolabs Original)

Types of our Solid Tumor Targeting CAR-T Development Services

We provide specialized engineering tracks to tailor the level of checkpoint modulation to your specific project needs:

Solid Tumor Targeting CAR-T Development Service with Checkpoint Blockade

This strategy enhances CAR-T durability and effector function by locally neutralizing checkpoint signaling, enabling sustained tumor killing and improved activity within immunosuppressive solid tumor microenvironments.

Solid Tumor Targeting CAR-T Development Service with Dominant-Negative TGF-βRII

By blocking TGF-β mediated suppression, this approach preserves CAR-T activation and proliferation, supporting effective tumor infiltration and long-term antitumor responses in solid tumors.

Key Advantages

Armored CAR-T Engineering: We engineer CAR-T cells to secrete checkpoint-blocking scFvs/antibodies locally, achieving high tumor-site concentration with reduced systemic exposure.
DNR Integration: CAR-T cells are equipped with decoy receptors to neutralize inhibitory ligands and sustain activity in suppressive TMEs.
Rigorous TME Validation: Each candidate undergoes repeated antigen stimulation cytotoxicity assays to verify enhanced persistence and effector function.
Multiplex Checkpoint Knockdown: For resistant tumors, we co-target multiple pathways to improve memory phenotypes and long-term efficacy in preclinical models.

FAQs

What is the main advantage of intrinsic checkpoint modulation over extrinsic antibody combination?

Intrinsic modulation, such as gene knockout or scFv secretion, ensures the blockade is localized to the tumor site, potentially reducing systemic toxicities and eliminating the need for repeated antibody dosing.

Does knocking out PD-1 affect the safety of the CAR-T cells?

While gene disruption is highly effective, it may lead to terminal differentiation in some contexts. We provide extensive phenotypic analysis to ensure your cells maintain a healthy memory/effector balance.

Can you target multiple checkpoints simultaneously?

Yes, we offer multiplexed gene editing to target dual or triple checkpoints, which have shown synergistic effects in increasing anti-tumor efficacy.

How do you validate that the checkpoint blockade is actually working?

We use co-culture assays with PD-L1-overexpressing tumor cells and measure cytokine release and markers of exhaustion via flow cytometry.

Partner with Us

Creative Biolabs provides the most advanced Solid Tumor Targeting CAR-T Development Services: Target Immune Checkpoint to help researchers overcome the critical barriers of T-cell exhaustion and TME immunosuppression. Our comprehensive workflow and proven expertise in checkpoint modulation ensure the development of highly effective and persistent therapeutic candidates. Contact us to discuss which strategy fits your trial design.

Reference

Alard, Emilie et al. “Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets.” Cancers vol. 12,7 1826. 7 Jul. 2020. Distributed under Open Access License CC BY 4.0, without modification. https://pmc.ncbi.nlm.nih.gov/articles/PMC7408985/

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.